Vertex Ventures HC
Vertex Ventures HC (VVHC) is a women-led, US-based healthcare venture capital firm investing in life science innovation worldwide. VVHC invests across biopharmaceuticals, medical devices and digital health, taking active board and portfolio roles from early/preclinical stages through commercial-stage companies. The firm operates from San Francisco and Boston and leverages a global Vertex network for cross-border business development, manufacturing and clinical collaboration.
Vertex Ventures HC
Palo Alto, California, United States, North America
Services
Equity investment (early to commercial stages)
Provides venture capital across company stages including early, preclinical, clinical and commercial-stage financings to build healthcare companies.
Active board-level and strategic guidance
Serves in active roles with portfolio companies, providing strategic guidance, board participation and hands-on portfolio support.
Networked business development and cross-border connections
Leverages the Vertex global network (US, China, Israel, Japan, SEA & India, Growth) to enable partnerships, business development, manufacturing and fundraising across geographies.
Portfolio clinical and regulatory support
Supports portfolio companies on clinical development strategy and regulatory interactions, including trial design and development pathway advice.
Fellowship and talent pipeline program
A fellowship program offering MD, PhD and PharmD students and recent graduates exposure to healthcare venture investing and portfolio management.
Equity investment (early to commercial stages)
Provides venture capital across company stages including early, preclinical, clinical and commercial-stage financings to build healthcare companies.
Active board-level and strategic guidance
Serves in active roles with portfolio companies, providing strategic guidance, board participation and hands-on portfolio support.
Networked business development and cross-border connections
Leverages the Vertex global network (US, China, Israel, Japan, SEA & India, Growth) to enable partnerships, business development, manufacturing and fundraising across geographies.
Portfolio clinical and regulatory support
Supports portfolio companies on clinical development strategy and regulatory interactions, including trial design and development pathway advice.
Fellowship and talent pipeline program
A fellowship program offering MD, PhD and PharmD students and recent graduates exposure to healthcare venture investing and portfolio management.
Portfolio
Developing ATX101, an ultra-sustained analgesic for post-surgical pain; Series D financing and IND/Phase 2b activity reported in 2025.
#Medtech / Biotech (post-surgical analgesia)
Developer of the MISHA Knee System (FDA cleared 2023); enrolling randomized controlled trial (MOTION RCT) as of 2025.
#Medtech (orthopedics, implantable shock absorber)
Developed an IOL-mounted long-term drug delivery platform for glaucoma; announced $75M Series D in June 2025 to support registrational Phase III trials.
#Ophthalmic biotech / drug-delivery
Developed a battery-free percutaneous sacral neuromodulation (pSNM) system for urgency urinary incontinence; reported 6-month pivotal trial results in 2025.
#Medtech / Bioelectronic medicine
Developing OBX-115, an engineered TIL cell therapy; reported Phase 1 safety and efficacy data in advanced melanoma (ASCO 2025).
#Biotech (engineered cell and gene therapies)
Developer of the Hydrus Microstent for glaucoma; multiple clinical trials and regulatory milestones reported; listed as an acquired/IPO outcome in portfolio.
#Medtech (ophthalmology, MIGS devices)
Developing ATX101, an ultra-sustained analgesic for post-surgical pain; Series D financing and IND/Phase 2b activity reported in 2025.
#Medtech / Biotech (post-surgical analgesia)
Developer of the MISHA Knee System (FDA cleared 2023); enrolling randomized controlled trial (MOTION RCT) as of 2025.
#Medtech (orthopedics, implantable shock absorber)
Developed an IOL-mounted long-term drug delivery platform for glaucoma; announced $75M Series D in June 2025 to support registrational Phase III trials.
#Ophthalmic biotech / drug-delivery
Developed a battery-free percutaneous sacral neuromodulation (pSNM) system for urgency urinary incontinence; reported 6-month pivotal trial results in 2025.
#Medtech / Bioelectronic medicine
Developing OBX-115, an engineered TIL cell therapy; reported Phase 1 safety and efficacy data in advanced melanoma (ASCO 2025).
#Biotech (engineered cell and gene therapies)
Developer of the Hydrus Microstent for glaucoma; multiple clinical trials and regulatory milestones reported; listed as an acquired/IPO outcome in portfolio.
#Medtech (ophthalmology, MIGS devices)